Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: JAMA Oncol. 2017 Aug 1;3(8):1094–1101. doi: 10.1001/jamaoncol.2017.0184

Figure 2. Clinical Outcome After HER2–Chimeric Antigen Receptor Virus-Specific T-Cell (HER2-CAR VST) Infusions.

Figure 2

A, Magnetic resonance imaging (MRI) scan of the brain before and 6 weeks after HER2-CAR VST infusion. The MRI scan of patient 4 shows a partial response (PR); MRI scans of patients 9 and 15 show increased edema after HER2-CAR VST infusions (yellow arrowheads outline the margin of edema). B, Swimmer plot showing disease status and overall survival in 17 patients treated with HER2-CAR VSTs. DL indicates dose level; PD, progressive disease; PR, partial response; and SD, stable disease.

aAlive.